Created On: 2020-07-15
Record Count: 11
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 299281
University also grants the right to enter into sublicensing agreements under the Patent Rights.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.
KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.
IPSCIO Record ID: 282837
For the Research License, Licensor grants an exclusive, with no right to grant sublicenses, under Licensor Patent Rights and Licensor Know-How to make and use methods and materials to carry out the Research Program during the Research Term.
For the Screening License, Licensor grants an exclusive, worldwide license during the term of this agreement to use the Collaboration compounds to conduct screening for anticancer activity.
For the Development and Commercialization License, Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor Patent Rights and Licensor Know-How, to make, use, and develop Collaboration Compounds, and, to make, have made, use, import, offer for sale, sell, and have sold products in the field.
This agreement includes a non-exclusive grant back from Licensee to Licensor.
Epothilone shall mean epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, desoxyepothilone F, and any intermediate, derivative, or analog of any of the foregoing compounds.
Product shall mean any pharmaceutical product containing a Collaboration Compound that is selected for development and/or marketing by Licensee or its Affiliates or Sublicensees.
Collaboration Compounds shall mean any Epothilone claimed in Licensor patent rights.
The field shall mean the research, development, manufacture, use, and sale of any Collaboration Compound for any purpose, including but not limited to all human and animal pharmaceutical and agricultural applications.
IPSCIO Record ID: 238988
Compound means any epothilone, or analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, a compound that is analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, and any compound identified in scientific journals or patent publications as an epothilon, analog, derivative, prodrug or metabolite.
Back-Up Compound means a Compound other than epothilone D that may be suitable for development for use in the Field, until and unless it comes to be included in a Replacement Licensed Product.
Licensed Product means any product containing a Compound, the Commercialization of which would either use Licensor Know-How, including without limitation because the product was researched or developed using Licensor Know-How or but for this Agreement, infringe a Valid Claim.
IPSCIO Record ID: 29382
The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.
IPSCIO Record ID: 256273
This agreement includes a non-exclusive grant by Licensee to Licensor.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
IPSCIO Record ID: 238982
6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer
Licensed Product(s) shall mean any product that:
(I) is covered in whole or in part by a Valid Claim of the Licensed Patents; or
(II) is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a Valid Claim of the Licensed Patents.
Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.
IPSCIO Record ID: 266840
Licensor Know-How shall mean the ideas, methods, characterization and techniques developed at the University before the Effective Date, which are necessary for practicing Licensor Patent Rights.
IPSCIO Record ID: 25786
SDX-102 is an intravenously administered small molecule which laboratory studies have shown kills tumors which cannot produce an important metabolic enzyme. Safety and tolerability data on SDX-102 were collected in clinical trials conducted at academic centers sponsored by the National Cancer Institute, or the NCI. These clinical trials tested the drug across a variety of cancers which are now known to produce this enzyme with a high frequency. The Licensee developed a proprietary, practical laboratory assay, or test, to identify patients whose cancers cannot produce this metabolic enzyme. In 2004, the Licensee was conducting Phase II trials of SDX-102 and are using their assay to select patients for these trials in difficult-to-treat cancers, including non-small cell lung cancer, or NSCLC, pancreatic and mesothelioma, none of which was previously studied by the NCI. The SDX-103 program involves analogs of the compound indanocine. Indanocine and indanocine analogs were synthesized and characterized at the University by the Licensee's founders. Indanocine displayed potent anti-proliferative activity when tested against a multitude of cancer cell lines at the NCI. These compounds differ from many clinically used drugs that block cell division in that they are active against multi-drug resistant cells and selectively kill non-dividing malignant cells. Anti-tumor activity of SDX-103 analogs has been observed in preliminary animal studies.
IPSCIO Record ID: 248277
The Institute hereby grants to Licensor an exclusive option to exclusively license any and all Improvement Inventions and Non-Improvement Inventions (the Option).
U.S. Patent Application #61/392,296 – Small Molecules Inhibiting Oncoprotein MYC
U.S. Patent Application #61/423,832 – Small Molecules inhibiting Oncoprotein MYC
Licensed Product shall mean any and all products that employ or are in any way contains or is made or produced using, or by the practice of the Licensed Patents, licensed Improvement Inventions, the Technology, or the Know-How, including the drug candidates set forth.
Â· Drug summary: MYC inhibitor.
Â· Indications: Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies (various types of leukemia and lymphoma).
Â· Mechanism of action: CBLC-M compounds were generated to selectively target and inactivate oncoproteins of the Myc family, which are frequently upregulated in tumor cells. Although Myc has long been recognized as a highly attractive target for anti-cancer treatment, there are no experimental
or approved drugs targeting this transcription factor. CBLC-M compounds target Myc family proteins with a high degree of specificity and cause their selective degradation. This mechanism of action is translated into both a direct tumor-suppressive effect and increased susceptibility of tumor cells to conventional chemotherapeutic drugs. Combining CBLC-M with such drugs as doxorubicin, 5FU, irinotecan and others within composite nanoparticles will result in improved anti-tumor effects due to precise targeted drug delivery that will concentrate the synergistic effects of the combined compounds on the tumor cells while reducing toxicity to normal cells.
Option Products shall mean Licensed Products and any and all products that employ or are in any way contained or made or produced using, or by the practice of the Projects set forth.
Improvement Invention shall mean any Institute Invention and Instituteâ€™s rights as a joint owner in a Joint Invention that is sufficiently different from the scope of a Licensed Patent to be separately patentable, and covered by the claims of Licensed Patents.
Non-Improvement Invention shall mean any Institute Invention and Instituteâ€™s rights as a joint owner in a Joint Invention that is not an Improvement Invention.
IPSCIO Record ID: 293074
Licensed Product shall mean AGX-A or its analogs as described in the Patent Rights, related products and processes.
AGX-A shall mean the compound N-benzyl-3-(4-isopropoxyphenyl)-3-(2-methoxyphenyl)propan-1-amine and includes pharmaceutically acceptable salts of N-benzyl-3-(4-isopropoxyphenyl)-3-(2-methoxyphenyl)propan-1-amine as described in U.S. Provisional Application No. 62/909,036 filed October 1, 2019. )
The scientific team has in its recent in vitro and in vivo work identified a biological mechanism that allows certain fatal cancers of the liver, brain and breast to regenerate despite their apparent elimination by surgery, chemotherapy or radiation.
IPSCIO Record ID: 4661